Evidence map›Paper›PMID 33843999›Full record

ArticleJAMA network open2021

Evaluation of the Cancer Transition Theory in the US, Select European Nations, and Japan by Investigating Mortality of Infectious- and Noninfectious-Related Cancers, 1950-2018.

Omer Gersten, Magali Barbieri

2 registry-linked trialsAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07040943 phase1completednot on this mapstarted 2025, after this paper: background citation

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.

TypeinterventionalSponsorWest China HospitalRan2025 to 2026Enrolled6ConditionsRefractory Malignant Solid Tumors, mRNA Vaccine, InterleukinArmsIL-22BP
NCT07100210 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of IL-22BP/LNP Compound in Refractory Malignant Solid Tumors

TypeinterventionalSponsorXingchen PengRan2025 to 2026Enrolled6ConditionsRefractory Malignant Solid Tumors, mRNA Vaccine, InterleukinArmsIL-22BP mRNA vaccine injection
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A comprehensive review of discovery and development of drugs discovered from 2020-2022.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Omer GerstenNu-Trek, San Diego, California.
Magali BarbieriDepartment of Demography, University of California, Berkeley.

Funding

Program Development (Pilot)P30AG012839 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI Magali Barbieri · 1999 to 2026
$18.6M
Monitoring Inter-County Variations in Mortality in the United StatesR03AG058110 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARBIERI, MAGALI · 2018 to 2019
$147k
NIA NIH HHS P30 AG012839NIA NIH HHS R03 AG058110
6 · The paper itself

Abstract

Importance: Despite cancer being a leading cause of death worldwide, scant research has been carried out on the validity of the cancer transition theory, the idea that as nations develop, they move from a situation where infectious-related cancers are prominent to one where noninfectious-related cancers dominate. Objective: To examine whether cancer transitions exist in the US, select European countries, and Japan. Design, Setting, and Participants: In this cross-sectional study, annual cause-of-death data from the 1950s to 2018 for the US, England and Wales, France, Sweden, Norway, and Japan were extracted from the Human Mortality Database and the World Health Organization (WHO). Statistical analysis was performed from April 2020 to February 2021. Main Outcomes and Measures: Age-standardized death rates for all ages and both sexes combined were estimated for cancers of the stomach, cervix, liver, lung, pancreas, esophagus, colorectum, breast, and prostate. Results: The results of the analysis show that for all countries in this study except for Japan, mortality from infectious-related cancers has declined steadily throughout the period, so that by the end of the period, for Norway, England and Wales, Sweden, and the US, rates were approximately 20 deaths per 100 000 population. Regarding noninfectious-related cancers, at the beginning of the period, all countries exhibited an increasing trend in rates, with England and Wales having the greatest peak of 215.1 deaths per 100 000 population (95% CI 213.7-216.6 deaths per 100 000 population) in 1985 followed by a decline, with most of the other countries reaching a peak around 1990 and declining thereafter. Furthermore, there is a visible crossover in the trends for infectious-related and noninfectious-related cancers in Japan and Norway. This crossover occurred in 1988 in Japan, when the rates for both types of cancers stood at 116 per 100 000 population (95% CI, 115.0-116.5 per 100 000 population), and in 1955 in Norway, when they passed each other at 100 per 100 000 population (95% CI, 96.4-105.3 per 100 000 population). Conclusions and Relevance: In this cross-sectional study, the findings suggest that cancer mortality patterns parallel the epidemiological transition, which states that as nations develop, they move from a stage where infectious diseases are prominent to one where noninfectious diseases dominate. An implication is that the epidemiological transition theory as originally formulated continues to be relevant, despite some researchers arguing that there should be additional stages beyond the original 3.

Indexed as

Cross-Sectional StudiesDatabases, FactualEuropeFemaleHumansJapanMaleNeoplasmsRetrospective StudiesUnited States

Identifiers

PMID33843999
PMCPMC8042523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.